SCHEMBL8965333

SCHEMBL8965333

CC(C)(C)c1nc(C(=O)O)co1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.35
ALOX15 P16050 2/20 0.35
TSHR P16473 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
ACMSD Q8TDX5 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
CES1 P23141 1/20 0.35
HIF1A Q16665 1/20 0.34
ALDH1A1 P00352 2/20 0.33
ELANE P08246 1/20 0.33
DAGLA Q9Y4D2 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
HDAC1 Q13547 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
KDM5A P29375 1/20 0.31
JMJD1C Q15652 1/20 0.31
KDM3A Q9Y4C1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1809200 0.86 ALOX15 (0.34) KDM4EALOX15TSHRTDP1ACMSD
SCHEMBL12597016 0.85 ALDH1A1 (0.34) KDM4EALOX15TSHRTDP1ACMSD
SCHEMBL28039212 0.85 CES1 (0.36) KDM4EALOX15TSHRTDP1ACMSD
SCHEMBL17281398 0.84 DAGLA (0.36) KDM4ETDP1IRAK4ALDH1A1DAGLA
SCHEMBL9459939 0.82 ALDH1A1 (0.46) TSHRIRAK4ALDH1A1KMT2AL3MBTL1
SCHEMBL12921449 0.82 CES1 (0.32) KDM4EALOX15TSHRTDP1ACMSD
SCHEMBL2481569 0.80 ASPH (0.37) KDM4EALOX15TSHRTDP1ACMSD
SCHEMBL77505 0.79 DAGLA (0.40) KDM4EIRAK4ALDH1A1DAGLAKMT2A
SCHEMBL26795642 0.79 IRAK4 (0.40) IRAK4HDAC1HDAC8HDAC6
SCHEMBL23123536 0.78 IRAK4 (0.33) IRAK4DAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
US-20250034150-A1 BTK INHIBITORS BIOGEN MA INC. 2025-01-30 US disclosed
WO-2025002177-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2025-01-02 WO disclosed
EP-4472968-A1 INHIBITORS OF RAF KINASES PIERRE FABRE MEDICAMENT (FR) 2024-12-11 EP disclosed
CN-118974036-A Inhibitors of RAF kinase 皮埃尔法布雷医药公司 2024-11-15 CN disclosed
US-20240327380-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2024-10-03 US disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 US disclosed
US-20240182467-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2024-06-06 US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 CN disclosed
US-20180194762-A1 PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2018-07-12 US disclosed
WO-2017193063-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES (US) 2017-11-09 WO disclosed
US-9783501-B2 Substituted quinolines as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-10-10 US disclosed
US-9139529-B2 Substituted quinoxalines as sodium channel modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-09-22 US disclosed
US-20140228371-A1 QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-14 US disclosed
EP-0459244-B1 Sulphonilised carboxylic acid amides BAYER AG (DE) 1996-02-28 EP disclosed
EP-0569810-A1 Sulphonylamide herbicides BAYER AG (DE) 1993-11-18 EP disclosed
US-5256632-A Pre- and postemergence BAYER AKTIENGESELLSCHAFT (DE) 1993-10-26 US disclosed
US-5205853-A Premergence and postemergence herbicides BAYER AKTIENGESELLSCHAFT (DE) 1993-04-27 US disclosed
EP-0459244-A1 Sulphonilised carboxylic acid amides BAYER AG (DE) 1991-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182467-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF KDM4E 1831/4885ALOX15 3665/4885TSHR 1226/4885
US-20240327380-A1 BTK INHIBITORS BTK, SYK, LYN KDM4E 1077/4885ALOX15 4708/4885TSHR 755/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 KDM4E 4646/4885ALOX15 639/4885TSHR 3921/4885
US-20180194762-A1 PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, SYK, LCK KDM4E 1076/4885ALOX15 2304/4885TSHR 2442/4885
US-20250034150-A1 BTK INHIBITORS BTK, SYK, LYN KDM4E 891/4885ALOX15 3957/4885TSHR 1899/4885
US-20140228371-A1 QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS SCN5A, SCN1A, SCN2A KDM4E 2141/4885ALOX15 2751/4885TSHR 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.